Provided by Tiger Trade Technology Pte. Ltd.

Castle Biosciences, Inc.

34.20
+1.273.86%
Post-market: 34.200.00000.00%19:30 EDT
Volume:573.47K
Turnover:19.47M
Market Cap:1.04B
PE:-52.28
High:34.70
Open:32.85
Low:32.14
Close:32.93
52wk High:44.28
52wk Low:17.72
Shares:30.55M
Float Shares:28.22M
Volume Ratio:1.54
T/O Rate:2.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6542
EPS(LYR):-0.8334
ROE:-4.20%
ROA:-1.36%
PB:2.22
PE(LYR):-41.03

Loading ...

Castle Bio CEO Derek Maetzold disposes 11,397 shares for USD 254,409.06

Reuters
·
May 12

Castle Biosciences Down Over 15%, on Pace for Largest Percent Decrease Since July 2024 -- Data Talk

Dow Jones
·
May 07

Castle Biosciences (CSTL) Gets a Buy from Lake Street

TIPRANKS
·
May 07

Castle Biosciences Is Maintained at Outperform by Baird

Dow Jones
·
May 07

Sweden's SciBase Q1 sees margin pressure on currency impact

Reuters
·
May 07

SciBase Q1 net loss widens to SEK 24.49 million; net sales rise 61% to SEK 14.28 million

Reuters
·
May 07

Castle Biosciences Q1 Adj. EPS $(0.49), Inline, Sales $83.700M Beat $79.415M Estimate

Benzinga Earnings
·
May 07

BRIEF-Castle Biosciences Q1 Revenue USD 83.679 Million Vs. IBES Estimate USD 79.4 Million

Reuters
·
May 07

Castle Biosciences Q1 Pretax Profit USD -14.413 Million

THOMSON REUTERS
·
May 07

Castle Biosciences Q1 EPS USD -0.49

THOMSON REUTERS
·
May 07

Castle Biosciences says Mayo Clinic data show TissueCypher shifts Barrett’s surveillance intervals 55%

Reuters
·
May 04

SciBase publishes 2025 annual report

Reuters
·
Apr 27

Castle Bio CEO Derek Maetzold disposes 4,450 common shares for $111,687.36

Reuters
·
Apr 24

Castle Biosciences presents new data on DecisionDx-Melanoma recurrence risk in early-stage patients

Reuters
·
Apr 21

Castle Biosciences Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Apr 21

Castle Biosciences price target lowered to $40 from $50 at Canaccord

TIPRANKS
·
Apr 20

Castle Biosciences schedules first-quarter results webcast

Reuters
·
Apr 15

Castle Biosciences CEO Derek Maetzold disposes of USD 155,581 common shares

Reuters
·
Apr 09

Castle Biosciences announces annual shareholder meeting

Reuters
·
Apr 08

SciBase study shows Nevisense predicts atopic dermatitis in newborns

Reuters
·
Apr 07